Alpha-galactosylceramide-CD1d complex (α-GalCer/CD1d)

The alpha-galactosylceramide (α-GalCer) presented by CD1d complex is a potent immunological entity formed by the binding of the glycolipid α-GalCer to the non-polymorphic MHC class I-like protein CD1d (Source: NIH, Caltag Medsystems). This complex serves as the primary ligand for the semi-invariant T-cell receptor (TCR) of invariant Natural Killer T (iNKT) cells, a specialized subset of lymphocytes that bridge innate and adaptive immunity (Source: NIH, Frontiers in Immunology). Upon engagement, iNKT cells rapidly secrete a broad spectrum of cytokines, including interferon-gamma (IFN-γ) and interleukin-4 (IL-4), which orchestrate the activation of downstream immune effectors like natural killer (NK) cells and dendritic cells (Source: NIH, ThermoFisher Scientific). Clinically, this complex is targeted to induce anti-tumor immunity in various cancers and to modulate immune responses in infectious and autoimmune conditions (Source: NIH, MDPI). However, therapeutic use is challenged by the induction of iNKT cell anergy, characterized by long-term unresponsiveness, and the potential for systemic cytokine-related toxicities (Source: Frontiers in Immunology, MDPI). Consequently, research focuses on developing optimized α-GalCer analogs and delivery systems to bias the immune response toward specific therapeutic outcomes (Source: NIH).

Other names

KRN7000/CD1d complexAlpha-GalCer/CD1d complexCD1d-alpha-galactosylceramideCD1d-lipid complex

Activation of invariant Natural Killer T (iNKT) cells through the T-cell receptor (TCR) upon recognition of the glycolipid-CD1d complex, leading to rapid secretion of Th1 and Th2 cytokines and subsequent transactivation of the innate and adaptive immune systems.